
    
      Patients fulfilling all eligibility criteria will be randomized in a 2:1 ratio in an
      open-label controlled design to treatment with rhC1-INH in addition to SOC or SOC only
      starting on day 0. The first rhC1-INH treatment will be administered on the same day and
      continued for a total of 4 days.
    
  